{"id":4437,"date":"2024-08-16T22:36:17","date_gmt":"2024-08-16T22:36:17","guid":{"rendered":"https:\/\/fehv.org\/?p=4437"},"modified":"2024-08-16T22:36:19","modified_gmt":"2024-08-16T22:36:19","slug":"efficacy-new-drugs-treatment-fatty-liver","status":"publish","type":"post","link":"https:\/\/fehv.org\/en\/efficacy-new-drugs-treatment-fatty-liver\/","title":{"rendered":"Efficacy of new drugs for the treatment of fatty liver"},"content":{"rendered":"\n<p style=\"font-size:18px\"><strong><a href=\"\/en\/diseases\/fatty-liver\/\">Fatty liver<\/a><\/strong> is a very common disease worldwide (it affects 25-30% of the population) and can have important repercussions on the liver, such as the development of cirrhosis and cancer, and on other organs (cardiovascular accidents, etc.). Currently <strong>there is no specific drug to cure the disease<\/strong> and therefore numerous clinical trials are being carried out with different agents.<\/p>\n\n\n\n<p style=\"font-size:18px\">Two studies on the administration of two new drugs to patients with fatty liver disease have recently been published in the <strong><a href=\"https:\/\/www.nejm.org\/\" target=\"_blank\" rel=\"noreferrer noopener\">New England Journal of Medicine<\/a><\/strong>. In one of them, Survodutide, which is a dual agonist directed at glucagon and glucagon-like peptide-1 receptors (with the potential to increase energy expenditure and reduce appetite), has been used. A total of 243 patients were included and were treated with a once-weekly subcutaneous injection of <strong>Survodutide<\/strong> at doses of 2.4, 4.8, or 6 mg or placebo for 48 weeks. <\/p>\n\n\n\n<p style=\"font-size:18px\">It was found that 47% of patients treated with 2.4 mg of <strong>Survodutide<\/strong>, 62% of those receiving 4.8 mg and 43% of those receiving 6 mg presented an improvement in the liver compared to 14% of those who received placebo. There was <strong>also a decrease in fibrosis<\/strong> (indicating disease progression) in 34% (2.4 mg), 36% (4.8 mg), 39% (6 mg) and in only 22% of those treated with placebo.<\/p>\n\n\n\n<h2 class=\"wp-block-heading mt-5 mb-4\" id=\"h-use-of-tirzepatide-for-the-fatty-liver-treatment\"><strong>Use of Tirzepatide for the fatty liver treatment<\/strong><\/h2>\n\n\n\n<p style=\"font-size:18px\">In the other study they used a similar drug, <strong>Tirzepatide <\/strong>(a dual agonist of glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors), which causes insulin secretion and reduces appetite. A total of 140 patients with fatty liver were included and treated weekly with a subcutaneous injection of Tirzepatide (5, 10 or 15 mg) or with placebo for 52 weeks. It was found that in patients who received the drug, there was an improvement in fatty liver in 44% (5 mg), 56% (10 mg) and 62% (15 mg) compared to 10% of those receiving placebo, with a improvement in fibrosis in 55%, 51%, 51% and 30%, respectively. Side effects of both drugs were mild and included nausea, diarrhea, and vomiting.<\/p>\n\n\n\n<p style=\"font-size:18px\">Very <strong>significant results have been obtained<\/strong> with these two drugs in the treatment of fatty liver. More studies need to be done with a larger number of patients and in the opinion of <strong><a href=\"\/en\/especialista\/dr-vicente-carreno\/\">Dr. Carre\u00f1o<\/a><\/strong> and the other doctors of the Foundation, these drugs will probably not be available as a treatment for fatty liver until at least 2026.<\/p>\n","protected":false},"excerpt":{"rendered":"Two recent studies reveal that Survodutide and Tirzepatide significantly improve the treatment of fatty liver by reducing fibrosis and enhancing liver health.","protected":false},"author":1,"featured_media":4435,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[623,621,624],"tags":[],"class_list":["post-4437","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-fatty-liver","category-news","category-treatments"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.7 (Yoast SEO v23.7) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Efficacy of new drugs for the treatment of fatty liver - Cl\u00ednica FEHV<\/title>\n<meta name=\"description\" content=\"Recent studies show that Survodutide and Tirzepatide have shown significant promise in the treatment of fatty liver.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/fehv.org\/en\/efficacy-new-drugs-treatment-fatty-liver\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Efficacy of new drugs for the treatment of fatty liver\" \/>\n<meta property=\"og:description\" content=\"Recent studies show that Survodutide and Tirzepatide have shown significant promise in the treatment of fatty liver.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/fehv.org\/en\/efficacy-new-drugs-treatment-fatty-liver\/\" \/>\n<meta property=\"og:site_name\" content=\"Cl\u00ednica FEHV\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/pages\/Fundacion%20Para%20el%20Estudio%20de%20las%20Hepatitis%20Virales\/228605694153917\/\" \/>\n<meta property=\"article:published_time\" content=\"2024-08-16T22:36:17+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-08-16T22:36:19+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/fehv.org\/wp-content\/uploads\/2024\/08\/eficacia-nuevos-farmacos-higado-graso.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1920\" \/>\n\t<meta property=\"og:image:height\" content=\"1280\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"ifranco\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"ifranco\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/fehv.org\/en\/efficacy-new-drugs-treatment-fatty-liver\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/fehv.org\/en\/efficacy-new-drugs-treatment-fatty-liver\/\"},\"author\":{\"name\":\"ifranco\",\"@id\":\"https:\/\/fehv.org\/#\/schema\/person\/5e92ddd4a04516dab21fb5b6fa90b777\"},\"headline\":\"Efficacy of new drugs for the treatment of fatty liver\",\"datePublished\":\"2024-08-16T22:36:17+00:00\",\"dateModified\":\"2024-08-16T22:36:19+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/fehv.org\/en\/efficacy-new-drugs-treatment-fatty-liver\/\"},\"wordCount\":374,\"publisher\":{\"@id\":\"https:\/\/fehv.org\/#organization\"},\"image\":{\"@id\":\"https:\/\/fehv.org\/en\/efficacy-new-drugs-treatment-fatty-liver\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/fehv.org\/wp-content\/uploads\/2024\/08\/eficacia-nuevos-farmacos-higado-graso.jpg\",\"articleSection\":[\"Fatty liver\",\"News\",\"Treatments\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/fehv.org\/en\/efficacy-new-drugs-treatment-fatty-liver\/\",\"url\":\"https:\/\/fehv.org\/en\/efficacy-new-drugs-treatment-fatty-liver\/\",\"name\":\"Efficacy of new drugs for the treatment of fatty liver - Cl\u00ednica FEHV\",\"isPartOf\":{\"@id\":\"https:\/\/fehv.org\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/fehv.org\/en\/efficacy-new-drugs-treatment-fatty-liver\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/fehv.org\/en\/efficacy-new-drugs-treatment-fatty-liver\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/fehv.org\/wp-content\/uploads\/2024\/08\/eficacia-nuevos-farmacos-higado-graso.jpg\",\"datePublished\":\"2024-08-16T22:36:17+00:00\",\"dateModified\":\"2024-08-16T22:36:19+00:00\",\"description\":\"Recent studies show that Survodutide and Tirzepatide have shown significant promise in the treatment of fatty liver.\",\"breadcrumb\":{\"@id\":\"https:\/\/fehv.org\/en\/efficacy-new-drugs-treatment-fatty-liver\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/fehv.org\/en\/efficacy-new-drugs-treatment-fatty-liver\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/fehv.org\/en\/efficacy-new-drugs-treatment-fatty-liver\/#primaryimage\",\"url\":\"https:\/\/fehv.org\/wp-content\/uploads\/2024\/08\/eficacia-nuevos-farmacos-higado-graso.jpg\",\"contentUrl\":\"https:\/\/fehv.org\/wp-content\/uploads\/2024\/08\/eficacia-nuevos-farmacos-higado-graso.jpg\",\"width\":1920,\"height\":1280,\"caption\":\"Inyecciones para el tratmaiento del h\u00edgado graso\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/fehv.org\/en\/efficacy-new-drugs-treatment-fatty-liver\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Portada\",\"item\":\"https:\/\/fehv.org\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Efficacy of new drugs for the treatment of fatty liver\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/fehv.org\/#website\",\"url\":\"https:\/\/fehv.org\/\",\"name\":\"Cl\u00ednica FEHV\",\"description\":\"Web de la Cl\u00ednica de la Fundaci\u00f3n para el Estudio de las Hepatitis Virales\",\"publisher\":{\"@id\":\"https:\/\/fehv.org\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/fehv.org\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/fehv.org\/#organization\",\"name\":\"Fundaci\u00f3n para el Estudio de las Hepatitis Virales - FEHV\",\"url\":\"https:\/\/fehv.org\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/fehv.org\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/fehv.org\/wp-content\/uploads\/2021\/03\/logo_fib-4.png\",\"contentUrl\":\"https:\/\/fehv.org\/wp-content\/uploads\/2021\/03\/logo_fib-4.png\",\"width\":47,\"height\":73,\"caption\":\"Fundaci\u00f3n para el Estudio de las Hepatitis Virales - FEHV\"},\"image\":{\"@id\":\"https:\/\/fehv.org\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/pages\/Fundacion Para el Estudio de las Hepatitis Virales\/228605694153917\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/fehv.org\/#\/schema\/person\/5e92ddd4a04516dab21fb5b6fa90b777\",\"name\":\"ifranco\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/fehv.org\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/aa877054d0216c55e7104c50647e81a8?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/aa877054d0216c55e7104c50647e81a8?s=96&d=mm&r=g\",\"caption\":\"ifranco\"}}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Efficacy of new drugs for the treatment of fatty liver - Cl\u00ednica FEHV","description":"Recent studies show that Survodutide and Tirzepatide have shown significant promise in the treatment of fatty liver.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/fehv.org\/en\/efficacy-new-drugs-treatment-fatty-liver\/","og_locale":"en_US","og_type":"article","og_title":"Efficacy of new drugs for the treatment of fatty liver","og_description":"Recent studies show that Survodutide and Tirzepatide have shown significant promise in the treatment of fatty liver.","og_url":"https:\/\/fehv.org\/en\/efficacy-new-drugs-treatment-fatty-liver\/","og_site_name":"Cl\u00ednica FEHV","article_publisher":"https:\/\/www.facebook.com\/pages\/Fundacion%20Para%20el%20Estudio%20de%20las%20Hepatitis%20Virales\/228605694153917\/","article_published_time":"2024-08-16T22:36:17+00:00","article_modified_time":"2024-08-16T22:36:19+00:00","og_image":[{"width":1920,"height":1280,"url":"https:\/\/fehv.org\/wp-content\/uploads\/2024\/08\/eficacia-nuevos-farmacos-higado-graso.jpg","type":"image\/jpeg"}],"author":"ifranco","twitter_card":"summary_large_image","twitter_misc":{"Written by":"ifranco","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/fehv.org\/en\/efficacy-new-drugs-treatment-fatty-liver\/#article","isPartOf":{"@id":"https:\/\/fehv.org\/en\/efficacy-new-drugs-treatment-fatty-liver\/"},"author":{"name":"ifranco","@id":"https:\/\/fehv.org\/#\/schema\/person\/5e92ddd4a04516dab21fb5b6fa90b777"},"headline":"Efficacy of new drugs for the treatment of fatty liver","datePublished":"2024-08-16T22:36:17+00:00","dateModified":"2024-08-16T22:36:19+00:00","mainEntityOfPage":{"@id":"https:\/\/fehv.org\/en\/efficacy-new-drugs-treatment-fatty-liver\/"},"wordCount":374,"publisher":{"@id":"https:\/\/fehv.org\/#organization"},"image":{"@id":"https:\/\/fehv.org\/en\/efficacy-new-drugs-treatment-fatty-liver\/#primaryimage"},"thumbnailUrl":"https:\/\/fehv.org\/wp-content\/uploads\/2024\/08\/eficacia-nuevos-farmacos-higado-graso.jpg","articleSection":["Fatty liver","News","Treatments"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/fehv.org\/en\/efficacy-new-drugs-treatment-fatty-liver\/","url":"https:\/\/fehv.org\/en\/efficacy-new-drugs-treatment-fatty-liver\/","name":"Efficacy of new drugs for the treatment of fatty liver - Cl\u00ednica FEHV","isPartOf":{"@id":"https:\/\/fehv.org\/#website"},"primaryImageOfPage":{"@id":"https:\/\/fehv.org\/en\/efficacy-new-drugs-treatment-fatty-liver\/#primaryimage"},"image":{"@id":"https:\/\/fehv.org\/en\/efficacy-new-drugs-treatment-fatty-liver\/#primaryimage"},"thumbnailUrl":"https:\/\/fehv.org\/wp-content\/uploads\/2024\/08\/eficacia-nuevos-farmacos-higado-graso.jpg","datePublished":"2024-08-16T22:36:17+00:00","dateModified":"2024-08-16T22:36:19+00:00","description":"Recent studies show that Survodutide and Tirzepatide have shown significant promise in the treatment of fatty liver.","breadcrumb":{"@id":"https:\/\/fehv.org\/en\/efficacy-new-drugs-treatment-fatty-liver\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/fehv.org\/en\/efficacy-new-drugs-treatment-fatty-liver\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/fehv.org\/en\/efficacy-new-drugs-treatment-fatty-liver\/#primaryimage","url":"https:\/\/fehv.org\/wp-content\/uploads\/2024\/08\/eficacia-nuevos-farmacos-higado-graso.jpg","contentUrl":"https:\/\/fehv.org\/wp-content\/uploads\/2024\/08\/eficacia-nuevos-farmacos-higado-graso.jpg","width":1920,"height":1280,"caption":"Inyecciones para el tratmaiento del h\u00edgado graso"},{"@type":"BreadcrumbList","@id":"https:\/\/fehv.org\/en\/efficacy-new-drugs-treatment-fatty-liver\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Portada","item":"https:\/\/fehv.org\/en\/"},{"@type":"ListItem","position":2,"name":"Efficacy of new drugs for the treatment of fatty liver"}]},{"@type":"WebSite","@id":"https:\/\/fehv.org\/#website","url":"https:\/\/fehv.org\/","name":"Cl\u00ednica FEHV","description":"Web de la Cl\u00ednica de la Fundaci\u00f3n para el Estudio de las Hepatitis Virales","publisher":{"@id":"https:\/\/fehv.org\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/fehv.org\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/fehv.org\/#organization","name":"Fundaci\u00f3n para el Estudio de las Hepatitis Virales - FEHV","url":"https:\/\/fehv.org\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/fehv.org\/#\/schema\/logo\/image\/","url":"https:\/\/fehv.org\/wp-content\/uploads\/2021\/03\/logo_fib-4.png","contentUrl":"https:\/\/fehv.org\/wp-content\/uploads\/2021\/03\/logo_fib-4.png","width":47,"height":73,"caption":"Fundaci\u00f3n para el Estudio de las Hepatitis Virales - FEHV"},"image":{"@id":"https:\/\/fehv.org\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/pages\/Fundacion Para el Estudio de las Hepatitis Virales\/228605694153917\/"]},{"@type":"Person","@id":"https:\/\/fehv.org\/#\/schema\/person\/5e92ddd4a04516dab21fb5b6fa90b777","name":"ifranco","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/fehv.org\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/aa877054d0216c55e7104c50647e81a8?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/aa877054d0216c55e7104c50647e81a8?s=96&d=mm&r=g","caption":"ifranco"}}]}},"_links":{"self":[{"href":"https:\/\/fehv.org\/en\/wp-json\/wp\/v2\/posts\/4437"}],"collection":[{"href":"https:\/\/fehv.org\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/fehv.org\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/fehv.org\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/fehv.org\/en\/wp-json\/wp\/v2\/comments?post=4437"}],"version-history":[{"count":1,"href":"https:\/\/fehv.org\/en\/wp-json\/wp\/v2\/posts\/4437\/revisions"}],"predecessor-version":[{"id":4438,"href":"https:\/\/fehv.org\/en\/wp-json\/wp\/v2\/posts\/4437\/revisions\/4438"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/fehv.org\/en\/wp-json\/wp\/v2\/media\/4435"}],"wp:attachment":[{"href":"https:\/\/fehv.org\/en\/wp-json\/wp\/v2\/media?parent=4437"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/fehv.org\/en\/wp-json\/wp\/v2\/categories?post=4437"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/fehv.org\/en\/wp-json\/wp\/v2\/tags?post=4437"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}